Evonik met with a delegation of representatives from Canada at its site in Darmstadt to discuss competencies in lipid nanoparticles at Evonik’s Vancouver laboratories and evaluate future collaboration opportunities.
Evonik has sites in seven locations in Canada including its Vancouver Laboratories in British Columbia for lipid-based parenteral drug delivery which plays a pivotal role in the rapid development and application of novel mRNA therapeutics. Consequently, the Covid-19 pandemic has accelerated the portfolio of system solutions for advanced drug delivery at Evonik Health Care, which is part of the life sciences division Nutrition & Care.
Among the delegation were the Canadian Minister of Innovation, Science and Industry, Honourable François-Philippe Champagne, and the Canadian Ambassador to Germany and Special Envoy to the European Union and Europe, Honourable Stéphane Dion.
Johann-Caspar Gammelin, President of the Nutrition & Care division, said: “We were honoured to welcome this delegation from Canada to Evonik Health Care. Much of the technical know-how and innovation leading to our success in lipids and lipid nanoparticles for mRNA therapeutics has been thanks to decades of experience at our laboratories in Vancouver.”
Honourable François-Philippe Champagne said: “We didn’t choose the timing of this pandemic and we will not choose the timing of the next health crisis, but we can choose to be better prepared. Canada’s Biomanufacturing and Life Sciences Strategy will build on areas of Canadian strength, including mRNA technologies. A robust Canadian life sciences ecosystem with participants like Evonik will help accelerate scientific discoveries to address global health challenges.”
Image credit: Evonik
